Drug Profile
PF 4603629
Alternative Names: PF-4603629Latest Information Update: 26 Jun 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 30 Sep 2008 Discontinued - Phase-I for Diabetes mellitus in USA (unspecified route)
- 28 Feb 2008 Phase-I clinical trials in Diabetes mellitus in USA (unspecified route)